SEC Form 25-NSE filed by PAVmed Inc.

4/30/25 4:06:48 PM ET

$PAVM

Medical/Dental Instruments

Health Care

Get the next $PAVM alert in real time by email

NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.

UNITED STATES

OMB APPROVAL

OMB Number:		3235-0080
Expires:	March 31, 2018
Estimated average burden
hours per response:		1.7

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 25

NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION
UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File Number

001-37685

Issuer:	PAVmed Inc.
Exchange:	Nasdaq Stock Market LLC

(Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)

Address:	One Grand Central Place, Suite 4600
	New York	NEW YORK	10165
Telephone number:				212-401-1951

(Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)

Series Z Warrants

(Description of class of securities)

Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:

17 CFR 240.12d2-2(a)(1)

17 CFR 240.12d2-2(a)(2)

17 CFR 240.12d2-2(a)(3)

17 CFR 240.12d2-2(a)(4)

Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. ¹

Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.

Pursuant to the requirements fo the Securities Exchange Act of 1934, Nasdaq Stock Market LLC certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.

2025-04-30	By	Tara Petta		AVP
Date		Name		Title

¹	Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Get the next $PAVM alert in real time by email

SEC Form 25-NSE filed by PAVmed Inc.

4/30/25 4:06:48 PM ET

$PAVM

Medical/Dental Instruments

Health Care

Get the next $PAVM alert in real time by email

NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.

UNITED STATES

OMB APPROVAL

OMB Number:		3235-0080
Expires:	March 31, 2018
Estimated average burden
hours per response:		1.7

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 25

NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION
UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File Number

001-37685

Issuer:	PAVmed Inc.
Exchange:	Nasdaq Stock Market LLC

(Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)

Address:	One Grand Central Place, Suite 4600
	New York	NEW YORK	10165
Telephone number:				212-401-1951

(Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)

Series Z Warrants

(Description of class of securities)

Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:

17 CFR 240.12d2-2(a)(1)

17 CFR 240.12d2-2(a)(2)

17 CFR 240.12d2-2(a)(3)

17 CFR 240.12d2-2(a)(4)

Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. ¹

2025-04-30	By	Tara Petta		AVP
Date		Name		Title

¹	Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Get the next $PAVM alert in real time by email

SEC Form 25-NSE filed by PAVmed Inc.

Crush Q3 2025 with the Best AI Executive Assistant

Recent Analyst Ratings for
$PAVM

SEC Form 25-NSE filed by PAVmed Inc.

Crush Q3 2025 with the Best AI Executive Assistant

Recent Analyst Ratings for
$PAVM

$PAVM
SEC Filings

PAVmed Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

PAVmed Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

Amendment: SEC Form SCHEDULE 13G/A filed by PAVmed Inc.

$PAVM
Press Releases

Fastest customizable press release news feed in the world

MolDX to Convene Expert Medical Panel on Medicare Local Coverage Determination (LCD) for Lucid Diagnostics' EsoGuard® Esophageal DNA Test

PAVmed Subsidiary Veris Health Completes $2.5 Million Direct Equity Financing

Major California Health System Launches Comprehensive Esophageal Precancer Testing Program Using Lucid Diagnostics' EsoGuard® Esophageal DNA Test

$PAVM
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Cantor Fitzgerald initiated coverage on PAVmed with a new price target

Lake Street Capital reiterated coverage on PAVmed with a new price target

$PAVM
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

New insider Tasso Partners, Llc claimed ownership of 2,574,350 shares (SEC Form 3)

SEC Form 4 filed by Director Agrawal Sundeep

SEC Form 4 filed by Director Agrawal Sundeep

$PAVM
Leadership Updates

Live Leadership Updates

Lucid Diagnostics to Join Russell 2000® and Russell 3000® Indexes

PAVmed Announces Efforts to Regain Compliance with Nasdaq Listing Requirements

Lucid Diagnostics Closes Series B / B-1 Preferred Stock Offering and Appoints Healthcare Industry Veteran Dennis Matheis to Board of Directors

$PAVM
Financials

Live finance-specific insights

PAVmed Provides Business Update and Reports First Quarter 2025 Financial Results

PAVmed to Hold a Business Update Conference Call and Webcast on May 15, 2025

Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 14, 2025

$PAVM
Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G filed by PAVmed Inc.

SEC Form SC 13G filed by PAVmed Inc.

SEC Form SC 13G filed by PAVmed Inc.

SEC Form 25-NSE filed by PAVmed Inc.

Crush Q3 2025 with the Best AI Executive Assistant

Recent Analyst Ratings for $PAVM

SEC Form 25-NSE filed by PAVmed Inc.

Crush Q3 2025 with the Best AI Executive Assistant

Recent Analyst Ratings for $PAVM

$PAVM SEC Filings

PAVmed Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

PAVmed Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

Amendment: SEC Form SCHEDULE 13G/A filed by PAVmed Inc.

$PAVM Press Releases

Fastest customizable press release news feed in the world

MolDX to Convene Expert Medical Panel on Medicare Local Coverage Determination (LCD) for Lucid Diagnostics' EsoGuard® Esophageal DNA Test

PAVmed Subsidiary Veris Health Completes $2.5 Million Direct Equity Financing

Major California Health System Launches Comprehensive Esophageal Precancer Testing Program Using Lucid Diagnostics' EsoGuard® Esophageal DNA Test

$PAVM Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Cantor Fitzgerald initiated coverage on PAVmed with a new price target

Lake Street Capital reiterated coverage on PAVmed with a new price target

$PAVM Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

New insider Tasso Partners, Llc claimed ownership of 2,574,350 shares (SEC Form 3)

SEC Form 4 filed by Director Agrawal Sundeep

SEC Form 4 filed by Director Agrawal Sundeep

$PAVM Leadership Updates

Live Leadership Updates

Lucid Diagnostics to Join Russell 2000® and Russell 3000® Indexes

PAVmed Announces Efforts to Regain Compliance with Nasdaq Listing Requirements

Lucid Diagnostics Closes Series B / B-1 Preferred Stock Offering and Appoints Healthcare Industry Veteran Dennis Matheis to Board of Directors

$PAVM Financials

Live finance-specific insights

PAVmed Provides Business Update and Reports First Quarter 2025 Financial Results

PAVmed to Hold a Business Update Conference Call and Webcast on May 15, 2025

Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 14, 2025

$PAVM Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G filed by PAVmed Inc.

SEC Form SC 13G filed by PAVmed Inc.

SEC Form SC 13G filed by PAVmed Inc.

Recent Analyst Ratings for
$PAVM

Recent Analyst Ratings for
$PAVM

$PAVM
SEC Filings

$PAVM
Press Releases

$PAVM
Analyst Ratings

$PAVM
Insider Trading

$PAVM
Leadership Updates

$PAVM
Financials

$PAVM
Large Ownership Changes